

## Instructor's Response(s) – Discussion Question(s) – Module 6

### **Discussion Question 1**

In an experiment in which cardiac fast action potentials were measured it was observed that administration of a particular drug resulted in a decrease in the duration of phase 2 along with more of a “droop” (negative slope) in phase 2. Please provide a possible explanation for these observations. Answer individually; **post your response to the Discussion Board by 9:00 PM of Day 4 of the module.**

The duration and “droop” (or lack thereof) of phase 2 of the cardiac fast action potential are determined by inward  $\text{Ca}^{2+}$  current (through, for the most part, L-type  $\text{Ca}^{2+}$  channels) and outward  $\text{K}^{+}$  currents ( $I_{K1}$ ,  $I_{Kr}$  and  $I_{Ks}$ ) – see video 2, slide 4 and video 3, slide 4.

So, one way to decrease the duration of phase 2, and to increase its “droop” is to reduce  $\text{Ca}^{2+}$  entry; this can be accomplished by administering a calcium channel blocker, such as diltiazem – see video 3, slide 3. The potentiation of outward  $\text{K}^{+}$  currents ( $I_{K1}$ ,  $I_{Kr}$  and  $I_{Ks}$ ) would (also) contribute to the observed effects (would require a drug different than diltiazem though).

### **Discussion Question 2**

What would be the effect of a drug that reduces T-type  $\text{Ca}^{2+}$  current on the time to reach threshold in a cardiac pacemaker potential? Briefly explain. Answer individually; **post your response to the Discussion Board by 9:00 PM of Day 5 of the module.**

The depolarization (phase 4, video 1, slide 3, panel A) to threshold (video 4, slide 5) of the cardiac pacemaker potential is determined by inward sodium ( $i_i$ ) and  $\text{Ca}^{2+}$  currents and an outward  $\text{K}^{+}$  current – see video 4, slides 3 and 4. In particular, there is a T-type  $\text{Ca}^{2+}$  current that occurs near the end of phase 4 (video 4, slide 4).

So – reducing the T-type  $\text{Ca}^{2+}$  current present near the end of phase 4 would delay depolarization to threshold (increase the time to reach threshold) in a cardiac pacemaker potential.

### **Discussion Question 3**

What would be the effect of a drug that reduced L-type  $\text{Ca}^{2+}$  current in AV nodal cells on the timing of the EKG waveform? Briefly explain. Answer individually; **post your response to the Discussion Board by 9:00 PM of Day 7 of the module.**

Conduction velocity in cardiac tissue is proportional to the amplitude of the AP and to the rate of change of membrane potential ( $V_m$ ) during phase 0 of the AP; higher amplitude and  $dV_m/dt$  during phase 0 lead to a higher conduction velocity

Rev 0, 2/27/17 - adapted from Spring 2016

Rev 1, 3/6/17 - correct typo (due day for Q2)

Rev 2, 9/25/17 - change color of text for due dates/times and add refs for B&L[7] to the Q3 response

Rev 3, 7/15/18 - up-date for 601; no content changes

Rev 4, 9/26/19 - change time due from 6:00 PM to 9:00 PM

(B&L[6+], pp 299-300; B&L[7], page 312). A reduction of L-type  $\text{Ca}^{2+}$  current in AV-nodal cells (e.g., by a calcium channel blocker) will blunt the amplitude of the action potential (B&L[6+], page 304; B&L[7], pp 316-317), thereby reducing conduction velocity through the AV node; the increased delay time through the AV node will be seen on the EKG as a prolonged P-R interval (video 6, slide 7). See also B&L[6+], pp 306-307; B&L[7], pp 318-319.

Rev 0, 2/27/17 - adapted from Spring 2016  
Rev 1, 3/6/17 - correct typo (due day for Q2)  
Rev 2, 9/25/17 - change color of text for due dates/times and add  
refs for B&L[7] to the Q3 response  
Rev 3, 7/15/18 - up-date for 601; no content changes  
Rev 4, 9/26/19 - change time due from 6:00 PM to 9:00 PM